Weaning Off Wegovy: What Happens When You Stop

What the STEP 1 data actually showed when participants stopped

The STEP 1 trial, published in the New England Journal of Medicine, ran for 68 weeks and then followed a subset of participants for a further year after treatment ended. The findings were striking: within 52 weeks of stopping, body weight had returned to within about 5 percentage points of baseline for many. Hunger, appetite and metabolic rate all began moving back towards pre-treatment patterns quickly.

This matters for anyone thinking about weaning off Wegovy because it tells us the medicine is doing active biological work the whole time you take it. Semaglutide binds GLP-1 receptors that regulate appetite signals in the brain; when it clears your system, those signals change again. That is not a character flaw or a lack of resolve. It is pharmacology.

The trial also showed that cardiometabolic markers improved during treatment largely tracked back towards baseline after stopping. So the conversation about when and how to stop is genuinely a clinical one, not just a practical convenience. If you want a thorough grounding in what semaglutide is and how it works in the body, the plain-English explanation of semaglutide on our site covers the mechanism in detail.

Is there a recommended tapering process for weaning off Wegovy in the UK?

Formally, no. The Wegovy prescribing information does not set out a mandatory dose-tapering schedule in the way that, say, long-term corticosteroids do. Some prescribers reduce the dose gradually over several weeks; others stop at the maintenance dose if clinical circumstances require. The NHS semaglutide guidance advises following your prescriber's or pharmacist's instructions and checking the patient information leaflet — and that guidance holds here too.

What that means practically: if you are thinking about stopping, start the conversation early. Do not simply let your prescription lapse or decide that one missed delivery is as good as stopping. A GPhC-registered prescriber can consider whether a step-down makes sense for you, or whether a planned pause with a clear re-start plan is safer. The question of whether you have to wean off Wegovy at all depends heavily on the dose you are on, your current weight and your reasons for stopping.

Reasons people stop vary considerably. Some reach a stable weight and feel ready. Some experience side effects that outweigh the benefit. Some face a cost change, if payday is late or a bank holiday pushes an order, it can tip into a decision to stop entirely. Whatever the reason, a short conversation with your prescriber is worth having before the last pen runs out.

Side effects and what to expect physically when you stop

Most people stopping Wegovy do not experience dramatic withdrawal symptoms in the pharmaceutical sense. There is no physical dependency in the way associated with some other medicines. What they do notice, usually within one to three weeks, is the return of appetite. Hunger that had felt absent or muted comes back. For some, this is manageable; for others, it arrives suddenly and feels unfamiliar after months of having little interest in food.

The gastrointestinal effects (nausea, slower gastric emptying) that some people experience on Wegovy resolve after stopping, generally within a few weeks as semaglutide clears. That is usually welcome. The harder adjustment is psychological: the sense of appetite being in charge again after a period when it was not. This is a question our prescribers hear regularly, and it is worth naming it as a real part of the stopping process rather than an afterthought.

If you stopped because of a side effect such as persistent nausea or a more serious symptom, it is worth logging that through the MHRA's Yellow Card scheme, which exists specifically to capture real-world safety experience with medicines like Wegovy. For context on how Wegovy is used across the full treatment journey, our Wegovy overview page covers the licensed doses and what to expect at each stage.

Planning what comes next: NHS pathways, private options and timing

If you are stopping Wegovy and wondering what the realistic next step is, the picture depends on why you started and whether your underlying weight-related conditions have changed. NICE's recommendation for semaglutide (TA875) specifies a maximum treatment duration of two years within a specialist weight management service on the NHS, so some patients reach a natural stopping point simply because the NHS pathway has run its course. Private prescriptions have no equivalent time limit, but clinical re-review before each repeat means no prescription continues indefinitely without a clinical rationale.

For those considering whether to stop, switch, or restart, reading through the options for how to approach stopping Wegovy gradually is a useful starting point. If cost is part of the equation, the Wegovy pricing guide sets out what private treatment typically involves and what a transparent, all-inclusive price should cover. For anyone at the beginning of a weight management journey rather than the end of one, our weight-loss treatment overview explains what the licensed options in the UK currently are. Every decision about continuing, pausing or stopping a prescription medicine deserves a real clinical conversation.